Tozorakimab Biosimilar – Anti-IL33 mAb – Research Grade

Introduction

Tozorakimab Biosimilar, also known as Anti-IL33 mAb, is a research grade antibody that targets the protein interleukin-33 (IL-33). This protein is a member of the IL-1 family and plays a crucial role in inflammatory responses and immune regulation. The development of Tozorakimab Biosimilar as a therapeutic agent has shown promising results in treating various inflammatory and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Tozorakimab Biosimilar in detail.

Structure of Tozorakimab Biosimilar

Tozorakimab Biosimilar is a monoclonal antibody (mAb) that is designed to specifically bind to IL-33. It is a recombinant protein produced in a laboratory using genetic engineering techniques. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for binding to IL-33.

Tozorakimab Biosimilar is a fully humanized antibody, meaning that it is derived from human genetic sequences and has minimal immunogenicity. This makes it a safe and effective therapeutic agent for human use.

Activity of Tozorakimab Biosimilar

The main activity of Tozorakimab Biosimilar is to block the activity of IL-33. IL-33 is a pro-inflammatory cytokine that is released by various cell types, including epithelial cells, fibroblasts, and endothelial cells, in response to tissue damage or infection. It binds to its receptor, ST2, and activates immune cells, such as T helper 2 (Th2) cells, mast cells, and eosinophils, to produce inflammatory mediators. This leads to the development of various inflammatory and autoimmune diseases, such as asthma, atopic dermatitis, and rheumatoid arthritis.

Tozorakimab Biosimilar binds to IL-33 and prevents it from binding to its receptor, thus inhibiting its pro-inflammatory activity. This results in the suppression of Th2 cell activation and the production of inflammatory mediators, leading to reduced inflammation and tissue damage.

Potential Applications of Tozorakimab Biosimilar

Tozorakimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various inflammatory and autoimmune diseases. Some of the potential applications of this antibody are:

Asthma Asthma is a chronic respiratory disease characterized by airway inflammation and narrowing. IL-33 has been shown to play a crucial role in the development of asthma by promoting Th2 cell activation and the production of inflammatory cytokines. Tozorakimab Biosimilar has been shown to effectively reduce airway inflammation and improve lung function in preclinical models of asthma. Clinical trials are currently underway to evaluate its efficacy in treating asthma in humans.

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin disorder characterized by intense itching, redness, and scaling. IL-33 has been implicated in the pathogenesis of atopic dermatitis by promoting inflammation and skin barrier dysfunction. Tozorakimab Biosimilar has shown promising results in reducing skin inflammation and improving skin barrier function in preclinical studies. Clinical trials are ongoing to assess its efficacy in treating atopic dermatitis in humans.

Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disease that causes inflammation and destruction of the joints. IL-33 has been shown to play a role in the development of

ProteoGenix catalogue number PX-TA1728. For research use only.

Target: Tozorakimab Biosimilar – Anti-IL33 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet